Filters: Author is Higano, Celestia S [Clear All Filters]
Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2014.
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.. The New England journal of medicine.. 2014.
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(11):3520-6.. 2011.
Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? Oncology (Williston Park, N.Y.). 28(8):700-1.. 2014.
Androgen deprivation for prostate cancer.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2013:176-83.. 2013.
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. The Canadian journal of urology. 22(6):8048-55.. 2015.
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.. The Journal of urology. 194(6):1537-47.. 2015.
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014.
HUMORAL IMMUNE RESPONSE AGAINST NON-TARGETED TUMOR ANTIGENS AFTER TREATMENT WITH SIPULEUCEL-T AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015.
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.. Clinical & experimental metastasis.. 2015.
New treatment options for patients with metastatic castration-resistant prostate cancer.. Cancer treatment reviews. 38(5):340-5.. 2012.
New developments in the treatment of castration-resistant prostate cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5 Suppl):773-6.. 2014.
To Treat or Not to Treat, That Is the Question: The Role of Bone-Targeted Therapy in Metastatic Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014.
New and emerging agents for the treatment of castration-resistant prostate cancer.. Urologic oncology. 29(6 Suppl):S1-8.. 2011.
Potential use of custirsen to treat prostate cancer.. OncoTargets and therapy. 6:785-97.. 2013.
Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.. 2010.
Intermittent versus continuous androgen deprivation therapy.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):727-33.. 2014.
Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(30):3720-5.. 2012.
Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.. Journal of molecular cell biology. 4(3):127-32.. 2012.
Doing Business with Arnold Library
Weintraub Building, B1-010
More About Arnold Library
- Journals List
- Ovid (guest or library account)
- Web of Science - Science Citation Index
- Pubmed (Get Article Enabled)
- Library Catalog (Account Login)
- Document Delivery Form
- Researcher Profiles
- Library Affiliations & Memberships
- Fred Hutch Authored Papers (Intranet)